Treacy Oliver, Brown Nigel N, Dimeski Goce
Department of Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital Ipswich Road, Woolloongabba, Queensland, Australia.
School of Medicine, University of Queensland, Brisbane, Australia.
Transl Androl Urol. 2019 May;8(Suppl 2):S214-S223. doi: 10.21037/tau.2018.10.02.
Different biochemical markers exist in both blood and urine for assessing renal function. Most of these biomarkers have advantages and limitations associated with their use, which is important to consider when ordering and utilising them in the clinical setting. The ideal marker should be able to detect acute kidney injury (AKI) at the onset and be used for the diagnosis and ongoing monitoring and management of kidney disease. The search for such a marker is ongoing, as all potential candidates thus far are associated with certain limitations. This article will attempt to compare and contrast established and emerging kidney disease markers.
血液和尿液中都存在不同的生化标志物用于评估肾功能。这些生物标志物大多在使用时都有其优点和局限性,在临床环境中开具和使用它们时,这一点很重要。理想的标志物应能够在急性肾损伤(AKI)发病时检测到,并用于肾脏疾病的诊断、持续监测和管理。目前仍在寻找这样一种标志物,因为迄今为止所有潜在的候选标志物都存在一定的局限性。本文将尝试比较和对比已有的和新出现的肾脏疾病标志物。